Drug Development

Study results of BBO-8520 and BBO-11818 will be presented in Chicago.

BDP’s role is to conjugate or tag the antibody (huMAb 3D1) to the toxin MMAE.

We provide autologous cell therapy products to support CD33- and GD2-targeted multicenter clinical trials in AML, neuroblastoma, and osteosarcoma.

We successfully produced multiple antibodies for immuno-oncology targets.

We led the sequencing consortium for NCI-MATCH, which set the stage for follow-on studies.

New isolation methods are making it faster and easier to discover natural products.

A growing body of evidence suggests that a single dose of vaccine against cancer-causing human papilloma virus (HPV) may protect as well as the standard two-or-more dose regimen. This would make it easier to protect more women, especially in low-income areas where vaccine access is scarce. A study published recently in The Lancet Global Health…

A research collaboration has made early progress toward a potential vaccine for type 1 diabetes, a long-sought goal for an autoimmune disease that affects more than 1.5 million Americans. The team, including Frederick National Laboratory computational scientist David Bell, previously discovered a new protein antibody in type 1 diabetes…

A research group including Frederick National Laboratory scientists has taken an early step toward a universal influenza vaccine that appears to protect against many strains, including the closely watched H5N1 bird flu. Human trials are under way. Conventional seasonal flu vaccines target the rapidly mutating head of the hemagglutinin (HA)…

Nanotechnology co-directors spoke at speaker series about modern vaccines and what the future may hold.